中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

安罗替尼治疗老年复发性肝门胆管癌1例报告

程思 陈宝 徐聂

引用本文:
Citation:

安罗替尼治疗老年复发性肝门胆管癌1例报告

DOI: 10.3969/j.issn.1001-5256.2020.06.032
基金项目: 

四川省卫生健康科研项目(19PJ174); 成都市医学科研课题(2019097); 2019年四川省中医药服务能力提升“十百千”工程县级中医医院建设项目; 

详细信息
  • 中图分类号: R735.8

A case of recurrent hilar cholangiocarcinoma in the elderly treated with anlotinib

Research funding: 

 

  • 摘要:

    <正>安罗替尼(anlotinib)是我国自主研发的新型多靶点小分子酪氨酸激酶抑制剂,能够抑制新生血管生成。相关动物试验[1]发现,安罗替尼能够抑制肿瘤生长,降低肿瘤内血管密度。2017年美国临床肿瘤学会年会[2]公布了安罗替尼三线治疗非小细胞肺癌的研究结果,与对照组比较总生存期显著延长(9. 6个月vs 6. 3个月),为治疗晚期非小细胞肺癌提供了新的治疗选择。多项临床Ⅱ、Ⅲ期研究[3-5]显示,安罗替尼

     

  • [1] XIE C,WAN X,QUAN H,et al. Preclinical characterization of anlotinib,a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor[J]. Cancer Sci,2018,109(4):1207-1219.
    [2] HAN B,LI K,WANG Q,et al. Effect of Anlotinib as a thirdline or further treatment on overall survival of patients with advanced non-small cell lung cancer:The ALTER 0303 phase 3randomized clinical trial[J]. JAMA Oncol,2018,4(11):1569-1575.
    [3] WANG G,SUN M,JIANG Y,et al. Anlotinib,a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma[J]. Int J Cancer,2019,145(4):979-993.
    [4] SUN YK,DU F,GAO M. Anlotinib for the treatment of patients with locally advanced or metastatic medullary thyroid cancer[J]. Thyroid,2018,28(11):1455-1461.
    [5] ZHONG CC,CHEN F,YANG JL,et al. Pharmacokinetics and disposition of anlotinib,an oral tyrosine kinase inhibitor,in experimental animal species[J]. Acta Pharmacol Sin,2018,39(6):1048-1063.
    [6] YIN XY. Controversy and strategy of preoperative biliary drainage reducing jaundice in hilar cholangiocarcinoma[J]. Chin J Dig Surg,2018,17(3):229-232.(in Chinese)殷晓煜.肝门部胆管癌术前行胆道引流术减轻黄疸的争议与策略[J].中华消化外科杂志,2018,17(3):229-232.
    [7] VALERO V,COSGROVE D,HERMAN JM,et al. Management of perihilar cholangiocareinoma in the era of multimodal therapy[J]. Expert Rev Gastroenterel Hepatol,2012,6(4):481-495.
    [8] MURAKAMI Y,UEMURA K,SUDO T,et al. Perineural invasion in extrahepatic cholangiocarcinoma:Prognostic impact and treatment strategies[J]. J Gastrointest Surg,2013,17(8):1429-1439.
    [9] CHEN XP,XIANG S. Therapy of hilar cholangiocarcinoma in the precise medicine period[J]. Chin J Dig Surg,2018,17(1):3-8.(in Chinese)陈孝平,项帅.精准医学时代肝门部胆管癌的治疗[J].中华消化外科杂志,2018,17(1):3-8.
    [10] YANG B,XIE H,WANG CP,et al. Study on inhibition of arotinib on human intrahepatic cholangiocarcinoma cell line HCCC-9810[J]. Chin J Med Guide,2017,19(12):1389-1391.(in Chinese)杨斌,谢辉,王春平,等.安罗替尼对人肝内胆管细胞癌细胞系HCCC-9810作用研究[J].中国医药导刊,2017,19(12):1389-1391.
    [11] ZHANG A,LIU B,XU D,et al. Advanced intrahepatic cholangiocarcinoma treated using anlotinib and microwave ablation:A case report[J]. Medicine(Baltimore),2019,98(52):e18435.
  • 加载中
计量
  • 文章访问数:  856
  • HTML全文浏览量:  12
  • PDF下载量:  121
  • 被引次数: 0
出版历程
  • 出版日期:  2020-06-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回